BioClinica, Inc. to Present at the Sidoti Semi-Annual Micro-Cap Conference on January 7, 2013 in New York City

BioClinica, Inc. to Present at the Sidoti Semi-Annual Micro-Cap Conference on January 7, 2013 in New York City

Company:Jim Dorsey, 267-757-3040orInvestor:Cheryl Schneider, 212-564-4700orFinancial Media:Bill Gordon, 212-564-4700

BioClinica®, Inc. (NASDAQ: BIOC), a leading global provider of clinical trial management solutions, today announced Mark L. Weinstein, President and Chief Executive Officer will be presenting at the Conference in New York City on Monday, January 7, 2013 at 1:30 p.m. EST.

Mr. Weinstein will be discussing an overview of BioClinica, its business strategy and financial performance. The company will also be hosting one-on-one meetings with investors at the conference. If you are interested in scheduling a one-on-one meeting, please contact your Sidoti representative or Cheryl Schneider, of Porter, LeVay & Rose, at 212-564-4700.

BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management solutions. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management and clinical supply chain design and optimization solutions. BioClinica solutions maximize efficiency and manageability throughout all phases of the clinical trial process. With over 20 years of experience and more than 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.